

Survival of Patients With Testicular Cancer in Lithuania During 1999–2002

Agnius Juška¹, Albertas Ulys², Laura Kairevičė³, Giedrė Smailytė⁴, Edgaras Stankevičius⁵, Rasa Jančiauskienė³, Mindaugas Jievaltas⁶

¹Faculty of Medicine, Vilnius University, ²Oncosurgery Center, Institute of Oncology, Vilnius University, ³Department of Oncology, Medical Academy, Lithuanian University of Health Sciences, ⁴Cancer Control and Prevention Center, Institute of Oncology, Vilnius University, ⁵Department of Physiology, Medical Academy, Lithuanian University of Health Sciences, ⁶Department of Urology, Medical Academy, Lithuanian University of Health Sciences, Lithuania

Key words: testicular cancer; survival; Kaplan-Meier method; log-rank test.

Summary. The aim of this study was to evaluate the survival of patients with testicular cancer in Lithuania during 1998–2002 and factors that influenced the survival.

Material and methods. The survival rates of testicular cancer patients were evaluated using the data of the Lithuanian Cancer Registry for 1998–2002. The survival was evaluated using the Kaplan-Meier method and log-rank test in order to compare the survival rates. The observed survival rates were calculated.

Results. The 5-year observed survival rate in Lithuania was 71.2% (95% CI, 64.4%–77.5%). The survival of testicular cancer patients depended on age at the time of diagnosis, histology of tumor, stage and extent of disease.

Conclusions. The survival of patients with testicular cancer in Lithuania was substantially lower than in other European countries. The better survival was associated with younger age and lesser extent of metastases.

Introduction

Testicular cancer (TC) is a rare malignant disease. Every year, an average of 49 000 new TC cases are diagnosed worldwide. It constitutes 0.8% of all malignant diseases in men (1, 2). The morbidity rate of TC in Lithuania is relatively low; in 1995, it accounted for 1.6 cases per 100 000 men (3). The highest morbidity rates have been observed in Western Europe (7.9 cases per 100 000 population), Northern Europe, Australia and New Zealand, as well as North America (5.4 cases per 100 000 population). The lowest morbidity rates due to TC are in Asia, e.g., in the Republic of China, the rate of TC accounts for 0.4 cases per 100 000 population (1, 2). The incidence of TC in Europe doubles every 20 years (4). Recently, a dramatic increase in TC morbidity has been reported from many countries. The causes of this trend are not known. The improvement of diagnostics may explain only a small part of this increase. Contrary to the morbidity rate, the death rate due to TC has been declining since the 1960s (1) and is very low (3.8 cases per 100 000 per year) (4).

In western countries, TC constitutes from 1% to 3% of all malignant tumors in men; however, in

most European countries, it is the most common malignant disease among young men aged 15 to 34 years (5). The highest mortality rate is observed among men aged 15 to 44 years, and in this age group, TC is the most common malignant disease in the developed countries (constitutes 13.4% of all new cancer cases). Testicular cancer is rarely responsible for death (9000 death cases worldwide). Over the last decades, positive outcomes of therapy have been associated with appropriate treatment using modern chemotherapy.

The survival of patients with TC in Lithuania has not been studied yet. The aim of our study was to evaluate the 5-year survival of patients diagnosed with TC during 1998–2002 as well as the factors influencing the survival.

Material and Methods

A retrospective descriptive study was carried out. The analysis of the survival was carried out using the data of the Lithuanian Cancer Registry. A total of 184 cases of TC were recorded in the database from December 1, 1998, to December 31, 2002. During this period, the fourth edition of the TNM system was used for coding the stage of disease. One

Correspondence to M. Jievaltas, Department of Urology, Medical Academy, Lithuanian University of Health Sciences, Eivenių 2, 50028 Kaunas, Lithuania. E-mail: minjiev@yahoo.com

Adresas susirašinėti: M. Jievaltas, LSMU MA Urologijos klinika, Eivenių 2, 50028 Kaunas. El. paštas: minjiev@yahoo.com

case of TC was excluded from the analysis because the disease was registered after patient's death only (the date of the first diagnosis was equal to the date of death). The overall survival of patients with TC as well as survival dependence on histological form of the tumor (seminoma/nonseminoma), stage, size, and the extent of spread of the tumor, and patient's age were studied. The starting point of the evaluation of survival time was defined as the date of the first diagnosis; the closing date was defined as the date of the end of follow-up (December 31, 2008) or the date of patient's death. Patient survival was evaluated by categories using the Kaplan-Meier method, and log-rank test was used for statistical comparison of the categories. Differences were considered significant when P value was <0.05 . Statistical analysis was carried out using STATA 7.0 software.

Results

The analysis of the survival included 183 patients who were diagnosed with TC from January 1, 1998, to December 31, 2002. The mean follow-up was 6.03 years (range, 0.008–10.63). During the follow-up, of the 183 patients, 55 died and 128 patients were alive at the end of the follow-up. Table 1 presents the distribution of patients by age and pathological and clinical characteristics of the tumor.

The 1-year survival of all patients with TC was 83.1% (95% CI, 76.8%–87.8%), and the 5-year survival reached 71.2% (95% CI, 64.4%–77.5%). The observed survival is shown in Fig. 1. Table 2 presents the 5-year survival of patients by age and pathological and clinical characteristics of the tumor.

Age. The 5-year survival rates for patients aged 15–29, 30–44, 45–64, 65 and more years were 71.4%, 79.6%, 56.5%, and 49.2%, respectively (Fig. 1). Patient's age at the time of diagnosis had a significant impact on the survival rate ($P=0.02$). The 5-year survival of patients older than 45 years was lower than 60%, while that of patients younger than 45 years exceeded 70%. Remarkably, patients aged 15–29 years demonstrated poorer survival than for those aged 30–44 years.

Tumor Histology. The survival rate for patients who were diagnosed with testicular seminomas was higher (80.7%) as compared with those diagnosed with nonseminomas (67.0%). The impact of histological form of the tumor on the survival was statistically significant ($P=0.0003$) (Fig. 2).

Stage. The stage of diagnosed disease had a significant effect on the patient survival ($P<0.0001$) (Fig. 3). The 5-year survival of the patients who were diagnosed with stage I cancer was 91.2%, while these rates were almost two-fold lower – less than 50% – in those with advanced disease (stages III and IV).

Tumor size. The 5-year survival was 89.4% when tumor T stage was T1, but when tumor was charac-

Table 1. The Distribution of Patients by Demographical, Pathological, and Clinical Characteristics

Characteristic	n	%
Age, years		
15–29	56	30.60
30–44	88	48.09
45–64	23	12.57
65 and more	16	8.74
Histology		
seminoma	83	45.36
nonseminoma	88	48.09
not indicated	12	6.56
Stage		
I	68	37.16
II	49	26.78
III	46	25.14
IV	11	6.01
not indicated	9	4.91
Tumor size (T)		
T1	47	25.68
T2	70	38.25
T3	34	18.58
T4	5	2.74
not indicated	27	14.75
Metastases in regional lymph nodes (N)		
N0	63	34.43
N1	17	9.29
N2	19	10.38
N3	8	4.37
not indicated	76	41.53
Distant metastases (M)		
M0	108	59.02
M1	30	16.39
not indicated	45	24.59




Fig. 1. The 5-year survival of patients with testicular cancer in Lithuania during 1998–2002 by age

terized as T2 at the time of diagnosis, the survival was 80.0%. When tumor T stage was T3 and T4, the survival rates were 50.0% and 60.0%, respectively. The higher survival rate when tumor stage was T4 may be influenced by other factors such as the number of infiltrated lymph nodes or the presence of distant metastases. The impact of tumor T stage on the 5-year survival was found to be statistically significant ($P<0.0001$) (Fig. 4).

Table 2. The 5-year Survival of Patients Diagnosed With Testicular Cancer in Lithuania During 1998–2002 by Demographical, Pathological, and Clinical Characteristics

Characteristic	Survival, %	95% CI
Age, years		
15–29	71.4	57.7–81.4
30–44	79.6	69.5–86.6
45–64	56.5	34.3–73.8
65 and more	49.2	23.6–70.6
Histology		
seminoma	80.7	70.42–87.7
nonseminoma	67.0	56.2–75.8
not indicated	41.7	15.3–66.5
Stage		
I	91.2	81.4–95.9
II	73.6	58.6–83.6
III	47.8	32.9–61.3
IV	45.5	16.7–70.7
not indicated	64.8	25.3–87.2
Tumor size (T)		
T1	89.4	76.3–95.4
T2	80.0	68.5–87.6
T3	50.0	32.4–65.3
T4	60.0	12.6–88.2
not indicated	47.9	28.3–65.0
Metastases in regional lymph nodes (N)		
N0	87.3	76.2–93.4
N1	64.7	37.7–82.3
N2	42.1	20.4–62.5
N3	62.5	22.9–86.1
not indicated	68.4	56.7–77.6
Distant metastases (M)		
M0	87.0	79.1–92.1
M1	33.3	17.5–50.0
not indicated	59.9	44.2–72.5

Metastases in Regional Lymph Nodes. The presence of metastases in regional lymph nodes also had a significant impact on the 5-year survival ($P=0.0013$). The highest survival rate (87.3%) was observed when nodal metastases were absent (N0). Discrepancy between survival rate and an increase in the number of metastatic lymph nodes (N) might be associated with the accuracy of evaluation of lymph nodes at the time of diagnosis.

Distant Metastases. When distant metastases were not present, the 5-year survival of those diagnosed with TC was 87.0%. Meanwhile, this rate was 33.3% for those who had distant metastases at the time of TC diagnosis. The presence or absence of distant metastases was a major determinant for the 5-year survival ($P<0.0001$).

Discussion

The majority of TCs (about 95%) are germ cell tumors that derive from testicular epithelium, and almost all of them are malignant. The overwhelming majority of germ cell tumors are localized in the testes; rarely primary tumors develop extragenitally (retroperitoneal space, mediastinum, brain, and others). However, the major part of germ cell tumors account




Fig. 2. The survival of patients diagnosed with testicular cancer in Lithuania during 1998–2002 according to tumor histological form




Fig. 3. The 5-year survival of patients diagnosed with testicular cancer in Lithuania during 1998–2002 by disease stage




Fig. 4. The 5-year survival of patients diagnosed with testicular cancer in Lithuania during 1998–2002 by tumor size (T)

for TC among young men. Germ cell tumors are different from the majority of solid tumors found in adults since they derive from embryonic cells (contrary to other tumors) and thus are more frequently found in young than older men (6).

Germ cell testicular tumors are traditionally classified into seminomas (40%) and nonseminomas (60%) (4). Both groups actually possess different mode of treatment, prognosis, and survival. Non-seminoma category comprises different types of tu-

mors (embryonic carcinoma, yolk sac tumor, teratoma, choriocarcinoma, etc.), including mixed cell type tumors (with or without seminoma component). Testicular stromal tumors (Leydig cells, Sertoli cells, granulosa cells, etc.) are found more rarely (7, 8). The growth of seminoma is slower and thus has a better prognosis than nonseminoma. Seminoma is sensitive to both radiotherapy and chemotherapy and has a good prognosis. Because of aggressive and rapid growth of nonseminomas, the age peak in those who are diagnosed with nonseminomas is 10 years earlier than in those with seminomas: the highest morbidity rates due to nonseminomas are observed in men aged 25–29 years, while due to seminomas, in men aged 35–39 years (9).

The survival of patients having neoplastic diseases commonly depends on multiple factors. The survival may be longer due to earlier diagnosis as well as effective treatment. The survival rates of country population do not only reflect the effectiveness of cancer treatment of certain localization, but they are also influenced by general diagnostic practice, treatment, observation of patients in existing health care system, methods of data collection and analysis, as well as tumor (histology, stage, and confirmation method) and patients' characteristics. The survival rates of population are important when evaluating the effectiveness of health care system and contribute to planning and evaluation of access to health care services in different regions of the country or different population groups (10).

The observed 5-year survival of patients with testicular cancer diagnosed in Lithuania during 1998–2002 was 71.2% (95% CI, 64.4%–77.5%). The survival for those diagnosed with TC is significantly better in other developed countries. According to the data of the EURO CARE-IV study, the relative 5-year survival in Europe was 94.2% in the early 1980s. However, poorer 5-year survival was documented in Baltic countries: the survival rate in Estonia (71.4%) was similar to that in Lithuania (11). It is thought that the differences in age structure or tumor biology cannot be responsible for the established survival

discrepancies among European countries.

The low survival rates of those diagnosed with TC in Lithuania cannot be associated with the prevalence of the histological forms of tumor – the proportion of diagnosed seminomas and nonseminomas is similar to other European countries. Among new cases of testicular malignant tumors diagnosed during 1998–2007, seminomas accounted for 44%, nonseminomas for 33%, and tumors with no histological form for 7% (12). In our opinion, the low survival rates might be influenced by the higher number of advanced TC in Lithuania due to late diagnosis. For instance, in the United Kingdom, stage I seminomas are diagnosed in 80% of patients and nonseminomas in approximately 60%, while in Lithuania stage I TCs are found only in 37% of patients (13). In our study, advanced stage of the disease was a major factor that significantly deteriorated the survival.

The other possible determinant influencing the survival is appropriate treatment (adjuvant chemotherapy in the first place). The effect of treatment on those diagnosed with TC has not been analyzed in the study; however, in the future a thorough analysis should be carried out taking into account treatment. Such an analysis would allow for more accurate evaluation of the effectiveness of treatment in terms of modern TC treatment schemas and how much this treatment influences the low survival rates of patients with TC.

Conclusions

The 1-year survival of patients diagnosed with testicular cancer was 83.1% (95% CI, 76.8%–87.8%), while the 5-year survival was 71.2% (95% CI, 64.4%–77.5%). The results of the analysis by different demographical, pathological, and clinical characteristics revealed that the significant factors influencing the survival of patients diagnosed with testicular cancer in Lithuania were as follows: patient's age at the time of diagnosis, tumor histological form, stage, tumor size, the number of affected lymph nodes, and the presence of distant metastases.

Susirgusiųjų sėklidžių vėžiu 1998–2002 išgyvenamumas Lietuvoje

Agnius Juška¹, Albertas Ulys², Laura Kairevičė³, Giedrė Smailytė⁴, Edgaras Stankevičius⁵,
Rasa Jančiauskienė³, Mindaugas Jievaltas⁶

¹Vilniaus universiteto Medicinos fakultetas, ²Vilniaus universiteto Onkologijos instituto Onkochirurgijos centras,

³Lietuvos sveikatos mokslų universiteto Medicinos akademijos Onkologijos klinika, ⁴Vilniaus universiteto Onkologijos instituto Vėžio kontrolės ir profilaktikos centras, ⁵Lietuvos sveikatos mokslų universiteto Medicinos akademijos Fiziologijos katedra, ⁶Lietuvos sveikatos mokslų universiteto Medicinos akademijos Urologijos klinika

Raktažodžiai: sėklidžių vėžys, išgyvenamumas, Kaplano–Meierio metodas, log-rank testas.

Santrauka. Tyrimo tikslas. Įvertinti 1998–2002 sėklidžių vėžiu susirgusių pacientų išgyvenamumą ir jam reikšmingos įtakos turinčius veiksnius.

Tyrimo medžiaga ir metodika. Išgyvenamumo tyrimui naudoti Lietuvos vėžio registro duomenys apie susirgusiuosius sėklidžių vėžiu 1998–2002. Pacientų, susirgusių sėklidžių vėžiu, penkerių metų išgyvenamumas įvertintas Kaplano–Meierio metodu, o išgyvenamumui palyginti naudotas log-rank testas.

Rezultatai. Lietuvoje susirgusiųjų sėklidžių vėžiu penkerių metų išgyvenamumas buvo 71,2 proc. (95 proc. PI 64,4–77,5). Šio tyrimo duomenimis, sėklidžių vėžiu susirgusiųjų išgyvenamumui reikšmingos įtakos turėjo paciento amžius diagnozės nustatymo metu, naviko histologinė forma ir stadija, kada diagnozuotas navikas (naviko dydis, pažeistų limfmazgių skaičius, tolimosios metastazės).

Išvada. Lietuvoje sėklidžių vėžiu susirgusiųjų išgyvenamumo rodikliai žymiai mažesni nei kitose Europos šalyse. Geresnis išgyvenamumas buvo susijęs su jaunesniu paciento amžiumi ir mažesniu naviko išplitimu.

References

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin* 2005;55:74–108.
2. Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5. Lyon: IARC; 2001.
3. Moller H, Evans H. Epidemiology of gonadal germ cell cancer in males and females. *APMIS* 2003;111:43–6.
4. Moller H, Friis S, Kjaer SK. Survival of Danish cancer patients 1943–1987. Male genital organs. *APMIS* 1993;Suppl 33:122–36.
5. Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C, et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). *Ann Oncol* 2004;15:1377–99.
6. Moller H. Clues to the aetiology of testicular germ cell tumours from descriptive epidemiology. *Eur Urol* 1993;23: 8–13.
7. Richiardi L, Bellocchio R, Adami HO, Barlow L, Hakulinen T, Rahu M, et al. Testicular cancer incidence in eight northern European countries: secular and recent trends. *Cancer Epidemiol Biomarkers Prev* 2004;13:2157–66.
8. STATA 8.0, Stata Corporation, 2003; College Station, Texas 77845 USA.
9. Parkin DM, Whelan SL, Ferlay J. Cancer incidence in five continents. Lyon: IARC; 2002. vol. 8. Publication no. 155.
10. Berrino F, Micheli A, Sant M, Capocaccia R. Interpreting survival differences and trends. *Tumouri* 1997;83:9–16.
11. Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J, et al. EURO-CARE-3: survival of cancer patients diagnosed 1990–94 – results and commentary. *Ann Oncol* 2003;14(Suppl 5):v61–118.
12. Smailytė G, Kačėnienė A, Ulys A, Kardelis Ž. Sėklidžių vėžys Lietuvoje 1978–2007 metais: paamžinės sergamumo struktūros ir histologinių formų dažnumo pokyčiai. (Testicular cancer in Lithuanian during 1978–2007: changes in morbidity and frequency of histological forms.) *Sveikatos mokslai* 2009;19:2787–91.
13. Horwich A, Shipley J, Huddart R. Testicular germ-cell cancer. *Lancet* 2006;367:754–65.
14. Schmoll HJ, Jordan K, Huddart R, Laguna MP, Horwich A, Fizazi K, et al. Testicular seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol* 2009;20(Suppl 4):83–9.

*Received 23 February 2010, accepted 6 January 2011
Straipsnis gautas 2010 02 23, priimtas 2011 01 06*